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.2012.06.Abstract Massive blood transfusion is replacement of a patient’s total blood volume in less than
24 h, or acute administration of more than half the patient’s estimated blood volume per hour. This
case report describes the clinical proﬁle, laboratory parameters and management of a post operative
patient who lost nearly double her blood volume in 36 h. A 27 yr old Indian woman with no history
of any medical illness, or co-morbidities underwent elective cesarean section for placenta praevia
totalis. The maximal allowable blood loss calculated for her weight with target haemoglobin of
10 g % was 450 ml. Though adequate haemostasis was achieved before closure, she had signiﬁcantly
increased bleeding PV 1 h post-operatively. Over the next 24 h she underwent a subtotal and then a
total hysterectomy. Blood loss within this period amounted to 6500 ml. The following day she lost
1900 ml blood through the drains. As is the approach to a surgical patient with massive blood loss,
it was ensured that the surgical cause of bleeding is controlled with simultaneous blood component
therapy so as to maintain haemostasis, blood oxygen carrying capacity, oncotic pressure and
plasma biochemistry. The patient received a total of 18 units Packed Red Blood Cells, 20 units
Fresh Frozen Plasma and six platelets over 36 h. The patient showed good recovery. Key points
in therapy include control and management of underlying cause, supportive treatment with appro-
priate blood components for maintaining tissue perfusion and oxygenation.
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0011. Introduction
Massive blood loss is usually deﬁned as the loss of one blood
volume within a 24 h period [1], normal blood volume being
approximately 7% of ideal body weight in adults and 8–9%
in children. Alternative deﬁnitions include 50% blood volume
loss within 3 h or a rate of loss of 150 ml/min [2].osting by Elsevier B.V. Open access under CC BY-NC-ND license.
294 S. Chaturvedi et al.It is imperative to recognise major blood loss early and
institute effective action promptly if shock and its conse-
quences are to be prevented.
The aim of transfusion is maintenance of tissue perfusion
and oxygenation by restoration of blood volume and haemo-
globin, arrest of bleeding by treating any traumatic, surgical
or obstetric source judicious use of blood component therapy
to correct coagulopathy [3].
2. Case presentation
A 27 yr old Indian woman with no past history of any medical
illness, or co-morbidities underwent elective cesarean section
for placenta praevia totalis. She had history of previous CS
(for breech) under spinal anaesthesia and ovarian cystectomy
under general anaesthesia. Peri-operative period for both sur-
geries were uneventful. Pre-anaesthetic evaluation did not re-
veal any abnormal ﬁndings. Pre-operative haemoglobin was
11.0 g %, blood group O +ve, and coagulation proﬁle was
normal. Written informed consent for surgery and anaesthesia
was taken and the possibility of hysterectomy/placenta accreta
was explained.
LSCS was performed under subarachnoid block. Estimated
Blood Loss (EBL) was 750 ml; maximal allowable blood loss
(MABL) was 440 ml for target Hb of 10 g %. One unit PRBC
was given during the surgery. Good haemostasis was achieved,
uterus well contracted, patient was shifted to ICU on syntoci-
non infusion. Intra-operative period was uneventful.
An hour after completion of surgery, she developed bleed-
ing per vaginum. The bleeding was transiently reduced follow-
ing carboprost injection, but recurred after 2 h.
Decision to perform subtotal hysterectomy was taken. At
that time the patient had tachycardia (HR – 130/min, regular),
but was hemodynamically stable (BP – 110/80).
Surgery revealed friable and bleeding lower uterine segment
with adherent placental tissue. Subtotal hysterectomy was
done, during which the patient was transfused with three units
packed cells. Two wide bore peripheral lines (14 G) and a ra-
dial arterial line were inserted. Estimated blood loss during
surgery was 1500 ml, urine output was 200 ml. Post-opera-
tively drains continued to ﬁll and four units PRBC were given,
along with two units of Fresh Frozen Plasma (FFP) in the
immediate post operative period. Differential diagnoses con-
sidered were surgical bleeding or disseminated intravascular
coagulation (DIC).Table 1 Blood components transfused and laboratory parameters.
Date/Time Hb Platelets
D1 Intraop (LSCS) 11 206
16:30 Intraop (Subtotal hyst) 6.9 150
19.00 NA NA
21.50 7.7 106
D2 – 00.30 5.2 30
03.30 6.5 65
07.30 NA NA
08.30 Intraop (Laparotomy) 6.2 85
12:15 4.6 50
15:30 10.5 60
D3-08:00 11.3 74Surgical and medical consultations sought were of the opin-
ion that conservative management be continued as the clinical
picture favoured DIC. After about 11 h postoperative, it was
decided to electively intubate & ventilate in view of continued
bleeding and severe anaemia, so as to reduce the work of
breathing. By next morning, the patient had lost 4500 ml blood
via the drains and had received 12 units PRBC, 10 units FFP,
four units platelets. Urine output continued to decline and
drains continued to ﬁll. Emergency exploratory laparotomy
was planned to rule out surgical cause of bleeding. Another
three units FFP were given prior to shifting to the operation
theatre (OT). Intra-operative ﬁndings revealed haemoperitone-
um with about 1250 ml blood and clots along with oozing
from raw surface of the stump. Haemostatic sutures were in-
serted and haemostasis established. Two units PRBC, one unit
FFP and one unit platelet concentrate were given inside the
theatre. The patient was shifted to ICU and continued on ven-
tilatory support. Bleeding continued from drains for another
2–3 h after which it gradually reduced and stopped.
Patient was extubated 4 h after laparotomy.
Post-operatively the patient received another four units
PRBC, two units FFP and one unit platelet. She was also given
20 ml of calcium gluconate after documenting hypocalcemia.
(Serum Calcium-6.5 mg %). Throughout the peri-operative
period and ICU stay, the laboratory parameters (Table 1)
and arterial blood gases (Table 2) were regularly monitored.
Total blood loss over 36 h was 8400 ml while the patients esti-
mated blood volume (66 · 70) was 4620 ml.
The patient received a total of 18 units Packed Red Blood
Cells, 20 units Fresh Frozen Plasma and six platelets over
36 h (Table 1). She showed good recovery, and after another
3 days in the ICU and 2 days in the ward she was discharged.
Her last report before discharge from the ICU showed Hb of
11.3 g %, haematocrit of 32.6, platelet count 74,000/cu mm,
and PT/INR, APTT within normal limits. The patient was last
seen 5 months after surgery and was doing well.
3. Discussion
Massive transfusion involves the selection of the appropriate
amounts and types of blood components to be administered,
and requires consideration of a number of issues including vol-
ume status, tissue oxygenation, management of bleeding and
coagulation abnormalities, as well as changes in ionised cal-
cium, potassium, and acid–base balance.PT/INR APTT Blood component
14/1.2 30.8 1 PRBC
NA NA 3 PRBC
22.5/2.1 43.8 2 PRBC, 2FFP
21/1.9 33.2 2 PRBC, 4 FFP
NA NA 2 PRBC, 4 Platelets
14.2/1.13 35.6 2 PRBC, 4 FFP
20.4/1.8 41 3 FFP
13.9/1.11 44.6 2 PRBC, 1 FFP, 1 Platelet
17.1/1.45 50 2 PRBC, 2 FFP, 1 Platelet
16.5/1.28 39.5 2 PRBC
NA NA
Table 2 Arterial blood gases on Day 1, Day 2 and Day 3.
Date/Time PaO2 PCO2 pH HCO3 BE Hb Comment
D1-14:12 351 34 7.31 17 8.7 6.5 Post hysterectomy
16:00 107 26 7.35 16 1.0 7.7
20:30 171 23 NA NA NA 5.5
D2-00:30 175 27 7.46 21 4 7.3
03:00 559 33 NA NA NA 7.5 Post intubation
06:30 172 30 7.45 22 2.4 6.8
10:15 185 35 NA NA NA 5.1 Post laparotomy
17:00 116 35 7.46 23 1.2 10 Post extubation
D3-08:30 78 29 7.47 23 2.0 10.8 On room air
D4-09.30 155 26 7.49 22 2.5 10.8
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The purpose of blood transfusion is to improve the oxygen-
carrying capacity of the blood. During the operative and
immediate postoperative period, intravascular volume and
haemoglobin concentration may change rapidly. The over-rid-
ing ﬁrst requirement is maintenance of tissue perfusion and
oxygenation, which is critical in preventing the development
of hypovolaemic shock and consequent high mortality from
multi-organ failure [4].
3.2. Monitoring
Frequent assessment of changing intravascular volumes, oxygen
delivery and patient physiology is required [4]. Blood samples
should be sent to the laboratory at the earliest possible opportu-
nity for blood grouping, antibody screening and compatibility
testing, as well as for baseline haematology, coagulation screen
and biochemistry investigations.When dealing with an evolving
process it is important to check parameters frequently, (and
after each therapeutic intervention) to monitor the need for
and the efﬁcacy of component therapy [4]. Temperature moni-
toring is important as hypothermia increases the risk of end or-
gan failure and coagulopathy and may be prevented by pre-
warming of resuscitation ﬂuids, patient warming devices such
as warm air blankets and the use of temperature controlled
blood warmers (Grade C recommendation, Level IV evidence).
3.3. Component therapy
Allogenic blood from volunteer donors is a limited and valu-
able resource that must be used carefully, appropriately and
safely.
3.4. Red blood cells
The function of red cells is oxygen delivery to tissues; they
should not be used as a volume expander [5]. Red cells also
contribute to haemostasis by their effect on platelet margin-
ation and function. The optimal haematocrit to prevent coag-
ulopathy is unknown, but experimental evidence suggests that
a relatively high haematocrit, possibly 35, may be required to
sustain haemostasis in patients with massive blood loss [6,7].
Red cell transfusion is likely to be required when 30–40%
blood volume is lost; over 40% blood volume loss is immedi-
ately life-threatening [8].3.5. Platelets
Expert consensus advises that the platelet count should not be
allowed to fall below the critical level of 50 · 109/l in the
acutely bleeding patient [9] (Grade C recommendation, level
IV evidence), and this is endorsed by the British Committee
for Standards in Haematology (BCSH) guidelines for the use
of platelet transfusions[10]. A platelet count of 50 · 109/l
may be anticipated when approximately two blood volumes
have been replaced by ﬂuid or red cell components [11] but
there is marked individual variation.
3.6. Fresh frozen plasma
Coagulation factor deﬁciency is the primary cause of coagu-
lopathy in massive transfusion because of dilution of coagula-
tion factors following volume replacement with crystalloid or
colloid and transfusion of red cell components. The level of
ﬁbrinogen falls ﬁrst; the critical level of 1.0 g/l is likely to be
reached after 150% blood volume loss, followed by the fall
of other labile coagulation factors to 25% activity after
200% blood loss [6]. Prolongation of the activated partial
thromboplastin time (APTT) and prothrombin time (PT) to
1.5 times the mean normal value is correlated with an increased
risk of clinical coagulopathy [12]. Although ‘formula replace-
ment’ with fresh plasma is not recommended, it may be re-
quired in situations where rapid turnaround of coagulation
tests cannot be guaranteed. Infusion of FFP should be consid-
ered after one blood volume is lost [13].
3.7. Complications of massive transfusion
Include coagulopathy, caused by a dilutional effect on the
host’s clotting factors and platelets, as well as the lack of plate-
lets and clotting factors in packed red blood cells, volume over-
load, hypothermia, hyperkalemia, metabolic alkalosis and
hypokalemia due to transfusion of a large amount of citrated
cells and hypocalcemia. Complex metabolic changes may oc-
cur due to hypovolaemia, hypothermia and the infusion of
large volumes of stored red cells and blood products, especially
plasma. The commonest is ionised hypocalcaemia due to cit-
rate toxicity [14]. Reduced ionised calcium reduces myocardial
contractility, causes vasodilation and exacerbates further
bleeding and shock. Hyperkalaemia may occur, due to the high
extracellular potassium concentration in stored red cell units.
This may be compounded by oliguria and the metabolic acido-
sis associated with shock [15].
Table 3 Key recommendations - British Committee for Standards in Haematology [3].
Goal Procedure Comments
Restore circulating volume Wide bore IV/central access Consider arterial line
Pre warmed colloid/crystalloid Monitor CVP
Avoid hypotension Warm patient
Urine output > 0.5 ml/kg/h Look for concealed bleeds
Contact key personnel Attending clinician ICU admission
Anaesthetist Designated person responsible for
communication &
Haematologist Documentation
Blood bank
Arrest bleeding Early surgical/OBG intervention
Interventional radiology
Laboratory investigations CBC, PT, APTT, TT, Fibrinogen, Correct patient identity
ABG, biochemical proﬁle Colloids may alter results
May need to give components before
results available
Maintain platelets > 75 Anticipate platelet < 50 after 2 x Allow margin of safety
Blood volume replacement Aim for platelet > 100 for multi/CNS
trauma
Maintain Hb > 8 Assess urgency
Blood salvage
Group O; Rh ve In emergency; O +ve acceptable
In males/post menopause
ABO group speciﬁc once known
Fully compatible blood
Use blood warmer/rapid infuser Time permitting
If ﬂow rate > 50 ml/kg/h in adults
Maintain PT & APTT
< 1.5 · control
FFP-12–15 ml/kg PT/APTT> 1.5 · control correlates with
increased micro-vascular bleeding
Anticipate need for FFP after 1–1.5 · blood vol replaced Keep ionised Ca > 1.13 mmol/l
Maintain ﬁbrinogen > 1.0 g/l If not corrected by FFP give 2 pools cryoprecipitate Rarely needed except in DIC
Avoid DIC Correct precipitating causes: shock, hypothermia, acidosis Rare but has high mortality
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mains an important clinical problem. It is an intricate, mul-
tifactorial and multicellular event. Disseminated
intravascular coagulation is a feared complication in the
acutely bleeding patient. The cardinal clinical sign of DIC
is microvascular oozing, whilst microthrombi in small vessels
can result in end-organ damage. A DIC-like syndrome can
result from the activation of the coagulation cascade second-
ary to tissue trauma, resulting in excessive consumption of
platelets and coagulation factors. Patients at particular risk
are those with tissue damage due to prolonged hypoxia,
hypovolaemia or hypothermia, and those with massive head
injury or extensive muscle damage [7]. This syndrome carries
a high mortality, and is difﬁcult to reverse. Prolongation of
the PT and APTT in excess of that expected by dilution, to-
gether with signiﬁcant thrombocytopenia and ﬁbrinogen of
<1.0 g/l are highly suggestive of a developing DIC-like state
and hence frequent estimation of platelet count, ﬁbrinogen,
PT and APTT is strongly recommended. Measurement of
D-dimer may also be useful in providing an early warning.
Laboratory evidence of a consumption coagulopathy should
be sought before microvascular bleeding becomes evident, so
that appropriate and aggressive action can be taken to ad-
dress the underlying cause [16]. Treatment strategies include
the maintenance of adequate tissue perfusion, the correction
of hypothermia and anaemia, and the use of haemostatic
blood products including platelets, FFP and cryoprecipitate
to correct microvascular bleeding, taking care to avoid circu-
latory overload [7].Transfusion-related acute lung injury (TRALI) and other
acute immunologically mediated reactions are uncommon,
but occur 5–6 times more frequently following administration
of platelets and FFP than red cells [15]. It is a severe acute
reaction characterised by respiratory distress, hypoxia and pul-
monary inﬁltrates soon after transfusion with no other appar-
ent cause. The reported incidence varies from 0.001% to
0.16% per patient transfused [16].
Acute haemorrhage leading to acute hypovolaemic shock is
a medical emergency associated with a high mortality, and re-
quires prompt and effective treatment [16]. A methodological
approach to a patient with massive blood loss is essential for
proper management. British Committee for standards in Hae-
matology key recommendations are given in Table 3. Key
points in therapy include control and management of underly-
ing cause, supportive treatment with appropriate blood com-
ponents for maintaining tissue perfusion and oxygenation. In
this case too surgical bleed was considered and the patient
re-explored, while simultaneously providing blood component
therapy as and when indicated by the laboratory parameters.
Repeated monitoring of arterial blood gases and haematolog-
ical tests helped guide us in ensuring a good outcome.References
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